Diabetes treatment developer Hua Medicine has completed a $25m Wuxi PharmaTech-backed round that boosted its overall funding to $75m.

China-based biotechnology company Hua Medicine closed a $25m series B round featuring Wuxi Ventures, the corporate venturing arm of medical research company Wuxi Pharmatech, today.

Investment platform Ally Bridge Group led the round, which also featured Sino-Alliance International Ltd (SAIL), an investment affiliate of semiconductor maker Shanghai Simic Electronics, as well as Frontline BioVentures, TF Capital, Arch Venture Partners, Venrock, and Fidelity.

Hua will use the funding to accelerate clinical development of its lead product candidate, a treatment for diabetes,…